Form 4: Immix Biopharma Director Magda Marquet Reports Share Acquisitions Following Merger

Director Magda Marquet reports acquisition of Immix Biopharma shares, including those received in exchange for Nexcella, Inc. stock following the merger.

Summary

• Magda Marquet, a director of Immix Biopharma, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 15, 2024, Marquet acquired 25,002 shares of common stock as a replacement for prior awards held in Nexcella, Inc., related to the merger with Immix Biopharma.
• These shares are restricted stock awards that will vest in thirteen equal monthly installments, contingent upon continued service with the Issuer.
• On May 20, 2024, Marquet acquired an additional 21,155 shares of common stock in exchange for shares of Nexcella, Inc., which merged with Immix Biopharma.
• Marquet also indirectly owns 20,000 shares through ALMA Life Sciences, LLC.
• Following these transactions, Marquet directly owns 46,092 shares of Immix Biopharma common stock and indirectly owns 20,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document primarily reports transactions related to a merger, which is neither inherently positive nor negative. The director's increased stake could be seen as a positive signal, but it's a standard part of the merger process.

Positives

• The acquisition of shares by a director could be seen as a positive sign, indicating confidence in the company's future after the merger.

Future Outlook

The restricted stock awards will vest in thirteen equal monthly installments following the date of grant, subject to the Reporting Person's continued service with the Issuer.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership of company stock, providing transparency to investors.

Stakeholder Impact

• Shareholders may view the increased ownership by a director as a sign of confidence in the company's future prospects.

Key Dates